492 lines
32 KiB
HTML
492 lines
32 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="zh-CN" data-theme="night">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<title>深度行研：医药化债概念</title>
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.11.1/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||
<script src="https://cdn.tailwindcss.com"></script>
|
||
<script src="//unpkg.com/alpinejs" defer></script>
|
||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||
<style>
|
||
@keyframes subtle-gradient {
|
||
0% { background-position: 0% 50%; }
|
||
50% { background-position: 100% 50%; }
|
||
100% { background-position: 0% 50%; }
|
||
}
|
||
|
||
body {
|
||
background-color: #000213;
|
||
background-image:
|
||
radial-gradient(ellipse at top, rgba(17, 34, 68, 0.3), transparent 60%),
|
||
radial-gradient(ellipse at bottom, rgba(30, 144, 255, 0.15), transparent 70%);
|
||
background-size: 400% 400%;
|
||
animation: subtle-gradient 25s ease infinite;
|
||
color: #e0e0e0;
|
||
font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
|
||
}
|
||
|
||
.glass-card {
|
||
background: rgba(10, 15, 40, 0.6);
|
||
backdrop-filter: blur(16px) saturate(180%);
|
||
-webkit-backdrop-filter: blur(16px) saturate(180%);
|
||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||
border-radius: 2rem; /* 极致圆角 */
|
||
transition: all 0.3s ease;
|
||
}
|
||
|
||
.glass-card:hover {
|
||
transform: translateY(-5px);
|
||
box-shadow: 0 20px 40px rgba(0, 0, 0, 0.3), 0 0 30px rgba(30, 144, 255, 0.2);
|
||
}
|
||
|
||
.bento-grid {
|
||
display: grid;
|
||
gap: 1.5rem;
|
||
grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
|
||
}
|
||
|
||
h1, h2, h3 {
|
||
text-shadow: 0 0 10px rgba(30, 144, 255, 0.5);
|
||
}
|
||
|
||
.glow-divider {
|
||
height: 2px;
|
||
background: linear-gradient(90deg, transparent, #4299e1, transparent);
|
||
border: none;
|
||
margin: 2rem 0;
|
||
}
|
||
|
||
.tab-active {
|
||
color: #60a5fa;
|
||
border-bottom-color: #60a5fa !important;
|
||
text-shadow: 0 0 8px #60a5fa;
|
||
}
|
||
|
||
.table th, .table td {
|
||
border-bottom-color: rgba(255, 255, 255, 0.1) !important;
|
||
}
|
||
</style>
|
||
</head>
|
||
<body class="min-h-screen p-4 sm:p-8">
|
||
|
||
<div class="max-w-7xl mx-auto space-y-12">
|
||
|
||
<!-- Header -->
|
||
<header class="text-center p-8 glass-card">
|
||
<h1 class="text-4xl md:text-6xl font-extrabold tracking-tight bg-clip-text text-transparent bg-gradient-to-r from-blue-300 via-cyan-300 to-indigo-400 mb-4">
|
||
深度行研：医药化债
|
||
</h1>
|
||
<p class="text-lg text-gray-400">双重逻辑驱动下的投资新范式</p>
|
||
<div class="mt-4 text-xs text-gray-500">
|
||
<p>由 北京价值前沿科技有限公司 AI投研agent：“价小前投研” 进行投研呈现</p>
|
||
<p class="font-semibold">本报告为AI合成数据，仅供研究参考，投资需谨慎。</p>
|
||
</div>
|
||
</header>
|
||
|
||
<!-- Insight Section -->
|
||
<main class="space-y-8">
|
||
<div class="glass-card p-6 md:p-8">
|
||
<h2 class="text-3xl font-bold mb-6 text-cyan-300">概念洞察 (Concept Insight)</h2>
|
||
|
||
<div class="space-y-6 text-gray-300">
|
||
<details class="collapse collapse-plus bg-base-200/30 rounded-2xl" open>
|
||
<summary class="collapse-title text-xl font-medium text-blue-300">核心观点摘要</summary>
|
||
<div class="collapse-content p-4">
|
||
<p>“医药化债”是一个典型的双重逻辑驱动概念，目前正处于<strong>政策驱动下的估值修复</strong>与<strong>产业自救下的价值发现</strong>并行阶段。其核心驱动力源自两个层面：一是宏观层面，政府通过化债政策改善对医药企业的支付能力，直接修复相关公司的资产负债表；二是微观层面，创新药企通过对外授权（License-out）等资本运作主动回笼资金，化解研发投入带来的财务压力。未来该概念的潜力取决于化债政策的实际落地速度与创新药企的持续“造血”能力，但市场对两种逻辑的混淆构成了主要的认知风险。</p>
|
||
</div>
|
||
</details>
|
||
|
||
<div class="p-6 bg-base-200/30 rounded-2xl">
|
||
<h3 class="text-2xl font-semibold mb-4 text-blue-300">概念事件与演进</h3>
|
||
<ul class="timeline timeline-compact timeline-vertical">
|
||
<li>
|
||
<div class="timeline-start timeline-box bg-transparent border-primary"><strong>前期 (~2023年中)</strong><br>医药流通、ICL等企业应收账款问题凸显，市场担忧坏账风险。</div>
|
||
<div class="timeline-middle"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-5 h-5 text-primary"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.857-9.809a.75.75 0 00-1.214-.882l-3.483 4.79-1.88-1.88a.75.75 0 10-1.06 1.061l2.5 2.5a.75.75 0 001.137-.089l4-5.5z" clip-rule="evenodd" /></svg></div>
|
||
<hr class="bg-primary"/>
|
||
</li>
|
||
<li>
|
||
<hr class="bg-primary"/>
|
||
<div class="timeline-middle"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-5 h-5 text-primary"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.857-9.809a.75.75 0 00-1.214-.882l-3.483 4.79-1.88-1.88a.75.75 0 10-1.06 1.061l2.5 2.5a.75.75 0 001.137-.089l4-5.5z" clip-rule="evenodd" /></svg></div>
|
||
<div class="timeline-end timeline-box bg-transparent border-primary"><strong>核心催化 (2023年Q4)</strong><br>中央层面“一揽子化债”政策（规模传闻达10万亿）出台，市场迅速解读为对G端业务重大利好。</div>
|
||
<hr class="bg-primary"/>
|
||
</li>
|
||
<li>
|
||
<hr class="bg-primary"/>
|
||
<div class="timeline-middle"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-5 h-5 text-primary"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.857-9.809a.75.75 0 00-1.214-.882l-3.483 4.79-1.88-1.88a.75.75 0 10-1.06 1.061l2.5 2.5a.75.75 0 001.137-.089l4-5.5z" clip-rule="evenodd" /></svg></div>
|
||
<div class="timeline-start timeline-box bg-transparent border-primary"><strong>发酵期 (2024年至今)</strong><br>市场持续跟踪化债进展。同时，创新药企通过License-out等方式主动“化债”的逻辑浮现，成为另一条主线。</div>
|
||
</li>
|
||
</ul>
|
||
</div>
|
||
|
||
<div class="p-6 bg-base-200/30 rounded-2xl">
|
||
<h3 class="text-2xl font-semibold mb-4 text-blue-300">核心逻辑与市场认知</h3>
|
||
<div class="grid grid-cols-1 md:grid-cols-2 gap-6">
|
||
<div class="p-4 border border-cyan-500/30 rounded-xl">
|
||
<h4 class="font-bold text-lg text-cyan-400">1. 宏观政策驱动 (被动受益)</h4>
|
||
<p class="mt-2 text-sm">根本逻辑是<strong>“政府信用修复”</strong>。地方政府通过化债获得流动性，清偿对公立医院的欠款，最终传导至上游供应商。本质是<strong>资产质量改善和现金流回归</strong>。新闻数据反复强调“清欠企业应收账款”、“改善三表质量”等，精准描述了此路径。</p>
|
||
</div>
|
||
<div class="p-4 border border-purple-500/30 rounded-xl">
|
||
<h4 class="font-bold text-lg text-purple-400">2. 微观自救驱动 (主动求生)</h4>
|
||
<p class="mt-2 text-sm">根本逻辑是<strong>“研发价值变现”</strong>。在资本寒冬下，创新药企通过License-out、并购等方式获取大额现金流，实现“自我造血”，化解债务风险。研报数据显示ADC领域交易火热，是典型企业级“化债”。</p>
|
||
</div>
|
||
</div>
|
||
<div class="mt-4 p-4 bg-yellow-900/20 border border-yellow-500/30 rounded-xl">
|
||
<h4 class="font-bold text-lg text-yellow-400">预期差分析</h4>
|
||
<p class="mt-2 text-sm"><strong>最大的预期差在于概念内涵的混淆</strong>。市场倾向于将两者笼统视为一个概念，但其公司画像、受益逻辑和风险收益特征截然不同。前者是<strong>业务成熟、受困于现金流的价值股</strong>；后者是<strong>高风险、高成长的科技股</strong>。此外，市场可能高估了政策回款的速度和规模。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="p-6 bg-base-200/30 rounded-2xl">
|
||
<h3 class="text-2xl font-semibold mb-4 text-blue-300">产业链与核心公司</h3>
|
||
<p class="mb-4">化债概念核心环节集中在中游的医药分销/流通企业和第三方服务商（如ICL），其下游客户主要是产生应收账款的公立医院等政府机构。</p>
|
||
<div class="overflow-x-auto">
|
||
<table class="table table-sm">
|
||
<thead>
|
||
<tr>
|
||
<th class="text-info">类型</th>
|
||
<th class="text-info">核心玩家</th>
|
||
<th class="text-info">逻辑</th>
|
||
<th class="text-info">关键特征</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr>
|
||
<td class="font-semibold">医药流通巨头</td>
|
||
<td>上海医药, 中国医药, 九州通</td>
|
||
<td>被动受益的“资产修复”型</td>
|
||
<td>应收账款体量巨大，国资背景在回款顺位上或有优势。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold">独立医学实验室(ICL)</td>
|
||
<td>迪安诊断, 金域医学</td>
|
||
<td>逻辑最纯粹的“困境反转”型</td>
|
||
<td>应收账款周转率极低，回款问题最严重，因此化债带来的业绩弹性最大。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold">企业自身“化债”</td>
|
||
<td>人福医药, 科伦博泰</td>
|
||
<td>主动求生的“自我造血”型</td>
|
||
<td>通过剥离非核心资产或对外授权（License-out）优化资本结构，确定性高。</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="p-6 bg-base-200/30 rounded-2xl">
|
||
<h3 class="text-2xl font-semibold mb-4 text-blue-300">潜在风险与投资启示</h3>
|
||
<div class="grid grid-cols-1 md:grid-cols-2 gap-6">
|
||
<div class="p-4 border border-red-500/30 rounded-xl space-y-2">
|
||
<h4 class="font-bold text-lg text-red-400">潜在风险</h4>
|
||
<ul class="list-disc list-inside text-sm space-y-1">
|
||
<li><strong>政策执行风险：</strong>化债进度、资金分配优先级和覆盖范围存在不确定性。</li>
|
||
<li><strong>商业模式风险：</strong>一次性财务修复不等于长期成长逻辑重塑。</li>
|
||
<li><strong>信息交叉验证风险：</strong>卖方乐观预期与企业端实证数据缺失存在矛盾。</li>
|
||
</ul>
|
||
</div>
|
||
<div class="p-4 border border-green-500/30 rounded-xl space-y-2">
|
||
<h4 class="font-bold text-lg text-green-400">投资启示与价值方向</h4>
|
||
<ul class="list-disc list-inside text-sm space-y-1">
|
||
<li><strong>困境反转型ICL企业：</strong>如迪安诊断、金域医学，逻辑最纯粹、赔率最高。</li>
|
||
<li><strong>全球竞争力的创新药平台：</strong>具备出海潜力管线的Biotech，确定性更高。</li>
|
||
<li><strong>需跟踪的关键指标：</strong>应收账款周转天数、经营性现金流、新增License-out交易额。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<hr class="glow-divider" />
|
||
|
||
<!-- Supporting Evidence Section -->
|
||
<div class="glass-card p-6 md:p-8" x-data="{ tab: 'news' }">
|
||
<h2 class="text-3xl font-bold mb-6 text-cyan-300">多源情报聚合 (Supporting Evidence)</h2>
|
||
<div class="tabs tabs-bordered mb-6">
|
||
<a class="tab tab-lg" :class="{ 'tab-active': tab === 'news' }" @click.prevent="tab = 'news'">新闻数据</a>
|
||
<a class="tab tab-lg" :class="{ 'tab-active': tab === 'roadshow' }" @click.prevent="tab = 'roadshow'">路演纪要</a>
|
||
<a class="tab tab-lg" :class="{ 'tab-active': tab === 'report' }" @click.prevent="tab = 'report'">研报精粹</a>
|
||
</div>
|
||
|
||
<div class="min-h-[300px]">
|
||
<div x-show="tab === 'news'">
|
||
<div class="space-y-4">
|
||
<div class="p-4 bg-base-200/50 rounded-xl">
|
||
<h4 class="font-semibold text-blue-300">核心逻辑</h4>
|
||
<p class="text-sm text-gray-300">地方政府通过化债腾出财力空间，加速偿还对公立医院的欠款，直接改善相关医药企业（ICL、设备商）的应收账款和现金流，修复资产负债表。</p>
|
||
</div>
|
||
<div class="p-4 bg-base-200/50 rounded-xl">
|
||
<h4 class="font-semibold text-blue-300">直接受益标的</h4>
|
||
<p class="text-sm text-gray-300">原文明确提及：<code class="text-yellow-300">[太阳]化债+医药 迪安诊断 金域医学</code>。同时，业务涉及科学仪器且有大量G端业务的聚光科技也被多方推荐。</p>
|
||
</div>
|
||
<div class="p-4 bg-base-200/50 rounded-xl">
|
||
<h4 class="font-semibold text-blue-300">通用影响机制</h4>
|
||
<p class="text-sm text-gray-300">化债政策强调“清欠企业应收账款”，将有效改善行业报表及现金流，实现“坏账计提减少甚至冲回增厚当期利润、应收降低改善负债结构提升现金流”。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div x-show="tab === 'roadshow'">
|
||
<div class="space-y-4">
|
||
<div class="p-4 bg-base-200/50 rounded-xl">
|
||
<h4 class="font-semibold text-purple-300">直接相关：企业自身“化债”</h4>
|
||
<p class="text-sm text-gray-300"><strong>人福医药(600079)</strong>：通过“归核化”战略，剥离非核心资产，将资产负债率从高位降至50%以下，持续压缩有息债务。这是企业层面的主动化债行为。</p>
|
||
</div>
|
||
<div class="p-4 bg-base-200/50 rounded-xl">
|
||
<h4 class="font-semibold text-purple-300">潜在相关：宏观背景影响</h4>
|
||
<ul class="list-disc list-inside text-sm space-y-1 text-gray-300">
|
||
<li>化债新政带来内需复苏预期，可能利好维生素等周期性医药品种。</li>
|
||
<li>化债政策提振市场风险偏好，医药板块成为主题轮动的一部分。</li>
|
||
<li>在化债热潮中，医药板块交易拥挤度相对较低，或存在补涨空间。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div x-show="tab === 'report'">
|
||
<div class="space-y-4">
|
||
<div class="p-4 bg-base-200/50 rounded-xl">
|
||
<h4 class="font-semibold text-green-300">核心发现：对外授权 (License-out) 成为化债关键途径</h4>
|
||
<p class="text-sm text-gray-300">在融资环境趋冷背景下，License-out成为中国药企回笼资金、缓解债务风险的核心手段。2023年交易总额高达<strong>408亿美元</strong>（同比+57%）。ADC领域尤其活跃，科伦博泰、百利天恒等通过授权获取高额首付款和里程碑付款。</p>
|
||
</div>
|
||
<div class="p-4 bg-base-200/50 rounded-xl">
|
||
<h4 class="font-semibold text-green-300">其他化债方式</h4>
|
||
<ul class="list-disc list-inside text-sm space-y-1 text-gray-300">
|
||
<li><strong>并购与合作：</strong>通过被大型药企收购（如礼来收购Morphic）或战略合作（百图生科与赛诺菲），直接获取资金或分摊风险。</li>
|
||
<li><strong>专利策略：</strong>通过发起专利无效诉讼，避免高额诉讼费用，直接化解潜在债务风险。</li>
|
||
<li><strong>政策影响：</strong>新药通过医保谈判后销售额爆发式增长，显著改善现金流，缓解债务压力。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<hr class="glow-divider" />
|
||
|
||
<!-- ECharts Visualization -->
|
||
<div class="glass-card p-6 md:p-8">
|
||
<h2 class="text-3xl font-bold mb-6 text-cyan-300">应收账款数据透视 (Accounts Receivable Analysis)</h2>
|
||
<p class="text-sm text-gray-400 mb-4">下图展示了部分医药化债概念股2023年的应收账款规模。高额的应收账款是这些公司面临的核心问题，也是化债政策能够带来显著改善的关键所在。</p>
|
||
<div id="receivables-chart" class="w-full h-[600px]"></div>
|
||
</div>
|
||
|
||
<hr class="glow-divider" />
|
||
|
||
<!-- Stock List Section -->
|
||
<div class="glass-card p-6 md:p-8">
|
||
<h2 class="text-3xl font-bold mb-6 text-cyan-300">核心标的池 (Core Stocks)</h2>
|
||
|
||
<div class="space-y-8">
|
||
<div>
|
||
<h3 class="text-xl font-semibold mb-4 text-blue-300">医药流通龙头</h3>
|
||
<div class="overflow-x-auto">
|
||
<table class="table w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>股票代码</th>
|
||
<th>核心逻辑</th>
|
||
<th>标签</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr>
|
||
<td>中国医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600056" target="_blank" class="link link-hover text-cyan-400">600056</a></td>
|
||
<td>线下医药流通龙头，实控人为央企，24Q3应收款项高达158亿。</td>
|
||
<td><div class="badge badge-primary badge-outline">央企</div> <div class="badge badge-secondary badge-outline">医药流通</div></td>
|
||
</tr>
|
||
<tr>
|
||
<td>嘉事堂</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=002462" target="_blank" class="link link-hover text-cyan-400">002462</a></td>
|
||
<td>一流医药流通服务商，实控人央企，24Q3应收账款高达76亿。</td>
|
||
<td><div class="badge badge-primary badge-outline">央企</div> <div class="badge badge-secondary badge-outline">医药流通</div></td>
|
||
</tr>
|
||
<tr>
|
||
<td>第一医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600833" target="_blank" class="link link-hover text-cyan-400">600833</a></td>
|
||
<td>上海地区老字号，实控人上海国资委，24Q3应收账款2.73亿。</td>
|
||
<td><div class="badge badge-accent badge-outline">上海国资</div> <div class="badge badge-secondary badge-outline">医药流通</div></td>
|
||
</tr>
|
||
<tr>
|
||
<td>南京医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600713" target="_blank" class="link link-hover text-cyan-400">600713</a></td>
|
||
<td>国内首家医药流通上市公司，终端和渠道网络良好。</td>
|
||
<td><div class="badge badge-accent badge-outline">南京国资</div> <div class="badge badge-secondary badge-outline">医药流通</div></td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
|
||
<div>
|
||
<h3 class="text-xl font-semibold mb-4 text-blue-300">财务数据对比 (2023年)</h3>
|
||
<div class="overflow-x-auto">
|
||
<table class="table w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>代码</th>
|
||
<th>应收账款 (亿)</th>
|
||
<th>应收账款周转率</th>
|
||
<th>归母净利润 (亿)</th>
|
||
<th>营业总收入 (亿)</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr>
|
||
<td>上海医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=601607" target="_blank" class="link link-hover text-cyan-400">601607.SH</a></td>
|
||
<td class="text-error font-bold">729.3</td>
|
||
<td>3.7</td>
|
||
<td>37.7</td>
|
||
<td>2603.0</td>
|
||
</tr>
|
||
<tr>
|
||
<td>重药控股</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=000950" target="_blank" class="link link-hover text-cyan-400">000950.SZ</a></td>
|
||
<td class="text-error font-bold">329.0</td>
|
||
<td class="text-warning">2.6</td>
|
||
<td>6.5</td>
|
||
<td>801.2</td>
|
||
</tr>
|
||
<tr>
|
||
<td>九州通</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600998" target="_blank" class="link link-hover text-cyan-400">600998.SH</a></td>
|
||
<td class="text-error font-bold">247.2</td>
|
||
<td>5.7</td>
|
||
<td>21.7</td>
|
||
<td>1501.4</td>
|
||
</tr>
|
||
<tr>
|
||
<td>中国医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600056" target="_blank" class="link link-hover text-cyan-400">600056.SH</a></td>
|
||
<td class="text-error font-bold">138.4</td>
|
||
<td class="text-warning">2.9</td>
|
||
<td>10.5</td>
|
||
<td>388.2</td>
|
||
</tr>
|
||
<tr>
|
||
<td>迪安诊断</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=300244" target="_blank" class="link link-hover text-cyan-400">300244.SZ</a></td>
|
||
<td class="text-error font-bold">80.5</td>
|
||
<td class="text-red-600 font-extrabold">1.5</td>
|
||
<td>3.1</td>
|
||
<td>134.1</td>
|
||
</tr>
|
||
<tr>
|
||
<td>金域医学</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=603882" target="_blank" class="link link-hover text-cyan-400">603882.SH</a></td>
|
||
<td class="text-error font-bold">53.4</td>
|
||
<td class="text-red-600 font-extrabold">1.4</td>
|
||
<td>6.4</td>
|
||
<td>85.4</td>
|
||
</tr>
|
||
<tr>
|
||
<td>人福医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600079" target="_blank" class="link link-hover text-cyan-400">600079.SH</a></td>
|
||
<td class="text-error font-bold">81.1</td>
|
||
<td class="text-warning">3.1</td>
|
||
<td>21.3</td>
|
||
<td>245.2</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
<p class="text-xs text-gray-500 mt-2">*注：应收账款周转率越低，表示回款越慢，受化债政策影响的弹性可能越大。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</main>
|
||
</div>
|
||
|
||
<script>
|
||
document.addEventListener('DOMContentLoaded', function () {
|
||
const chartDom = document.getElementById('receivables-chart');
|
||
const myChart = echarts.init(chartDom);
|
||
|
||
const chartData = [
|
||
{ value: 729.3, name: '上海医药' },
|
||
{ value: 329.0, name: '重药控股' },
|
||
{ value: 270.6, name: '智飞生物' },
|
||
{ value: 247.2, name: '九州通' },
|
||
{ value: 181.6, name: '国药一致' },
|
||
{ value: 173.6, name: '海王生物' },
|
||
{ value: 151.1, name: '白云山' },
|
||
{ value: 138.4, name: '中国医药' },
|
||
{ value: 117.4, name: '南京医药' },
|
||
{ value: 104.4, name: '柳药集团' },
|
||
{ value: 99.7, name: '云南白药' },
|
||
{ value: 89.6, name: '国药股份' },
|
||
{ value: 84.2, name: '嘉事堂' },
|
||
{ value: 81.1, name: '人福医药' },
|
||
{ value: 80.5, name: '迪安诊断' },
|
||
{ value: 79.0, name: '药明康德' },
|
||
{ value: 55.4, name: '润达医疗' },
|
||
{ value: 53.4, name: '金域医学' },
|
||
].sort((a, b) => a.value - b.value);
|
||
|
||
const option = {
|
||
backgroundColor: 'transparent',
|
||
tooltip: {
|
||
trigger: 'axis',
|
||
axisPointer: {
|
||
type: 'shadow'
|
||
},
|
||
formatter: '{b}<br/>应收账款: {c} 亿元',
|
||
backgroundColor: 'rgba(10, 15, 40, 0.8)',
|
||
borderColor: '#38bdf8',
|
||
textStyle: {
|
||
color: '#e0e0e0'
|
||
}
|
||
},
|
||
grid: {
|
||
left: '3%',
|
||
right: '4%',
|
||
bottom: '3%',
|
||
containLabel: true
|
||
},
|
||
xAxis: {
|
||
type: 'value',
|
||
boundaryGap: [0, 0.01],
|
||
axisLine: { lineStyle: { color: 'rgba(255, 255, 255, 0.3)' } },
|
||
splitLine: { lineStyle: { color: 'rgba(255, 255, 255, 0.1)' } },
|
||
axisLabel: { color: '#a0aec0' }
|
||
},
|
||
yAxis: {
|
||
type: 'category',
|
||
data: chartData.map(item => item.name),
|
||
axisLine: { show: true, lineStyle: { color: 'rgba(255, 255, 255, 0.3)' } },
|
||
axisLabel: { color: '#e0e0e0' }
|
||
},
|
||
series: [
|
||
{
|
||
name: '应收账款 (亿元)',
|
||
type: 'bar',
|
||
data: chartData.map(item => item.value),
|
||
itemStyle: {
|
||
color: new echarts.graphic.LinearGradient(0, 0, 1, 0, [
|
||
{ offset: 0, color: '#2563eb' },
|
||
{ offset: 1, color: '#38bdf8' }
|
||
]),
|
||
borderRadius: [0, 5, 5, 0],
|
||
shadowColor: 'rgba(56, 189, 248, 0.5)',
|
||
shadowBlur: 10
|
||
},
|
||
label: {
|
||
show: true,
|
||
position: 'right',
|
||
color: '#f0f9ff',
|
||
formatter: '{c}'
|
||
}
|
||
}
|
||
]
|
||
};
|
||
|
||
myChart.setOption(option);
|
||
window.addEventListener('resize', myChart.resize);
|
||
});
|
||
</script>
|
||
|
||
</body>
|
||
</html> |